DGAP-News: Biotest AG: Biotest increases operating result by EUR 20 million in 2018

PRESS RELEASE

Biotest increases operating result by EUR 20 million in 2018

- EBIT rises to EUR 10.6 million

- Sales grow by 5.9% to EUR 400.3 million

- Biotest meets sales and EBIT forecast

Dreieich, 07 March 2019. According to preliminary and unaudited figures, the Biotest Group increased sales in its continuing operations to EUR 400.3 million in the 2018 financial year. This corresponds to an increase of 5.9% over the previous year (EUR 378.1 million).

EBIT from continuing operations amounted to EUR 10.6 million in 2018 despite expenses of more than EUR 50 million for the "Biotest Next Level" expansion project. The previous year's EBIT in the amount of -9.3 million was burdened by the recall of a drug.

Revenues from discontinued operations amounted to EUR 6.0 million after EUR 163.1 million in the previous year.

The EBIT of the discontinued operation rose to EUR 194.1 million after
EUR 27.3 million in the previous year. The reasons for the increase were the capital gain of EUR 162.4 million from the sale of the US companies and the recognition of currency translation differences from deconsolidation in the income statement.

Biotest will publish the final figures for the fiscal year 2018 and the annual report on 28 March, 2019. The Annual General Meeting of Biotest AG will take place on 7 May 2019 in Frankfurt am Main.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.